Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Drug Product Stability

Drug Product Stability

The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Stability of Substituted Cyclohexanes

Stability of Substituted Cyclohexanes

This lesson discusses the stability of substituted cyclohexanes with a focus on energies of various conformers and the effect of 1,3-diaxial interactions.
The two chair conformations of cyclohexanes undergo rapid interconversion at room temperature. Both forms have identical energies and stabilities, each comprising equal amounts of the equilibrium mixture. Replacing a hydrogen atom with a functional group makes the two conformations energetically non-equivalent.
For example, in...

Drug Metabolism: Phase II Reactions

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High-Fidelity Bleeding Control Simulation Scenario During Medical Student Orientation Improves Students' Self-Reported Ability to Identify and Treat Life-Threatening Bleeding with 3-year Follow-up.

Journal of surgical education·2024

Same author

"It Feels Like Being a Real Doctor:" The Virtual Family Approach in Medical Education.

MedEdPublish (2016)·2024

Same author

Evaluation of a Palliative Care Longitudinal Curriculum for Medical Students Using the Context-Input-Process-Product Model.

The American journal of hospice & palliative care·2023

Same author

Defending Racial and Ethnic Diversity in Undergraduate and Medical School Admission Policies.

JAMA·2022

Same author

Implementing a Neurohospitalist Program Improves Stroke Care Metrics and Patient Satisfaction Scores.

The Neurohospitalist·2022

Same author

A comprehensive dataset describing nurse's emotions, perceived stressors and coping mechanisms during the first surge of the COVID-19 pandemic.

Data in brief·2022

Same journal

DNA, Peptide Vaccines Advance Against GBM.

Cancer discovery·2026

Same journal

AKR1C1 Promotes ADC Resistance by Altering Uptake and Export.

Cancer discovery·2026

Same journal

Acquisition of Centromeric Features Supports Telomere Integrity.

Cancer discovery·2026

Same journal

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026

Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026

Same journal

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 10, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Second chances for shelved compounds.

Cancer Discovery

|June 11, 2013

Summary

This summary is machine-generated.

Pharmaceutical companies are exploring shelved compounds for new applications. However, challenges like limited patent life make drug repurposing financially risky.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Experiment Videos

Last Updated: May 10, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Area of Science:

Drug discovery and development
Pharmaceutical sciences
Medicinal chemistry

Background:

Pharmaceutical companies are investigating previously shelved compounds for novel therapeutic applications.
The strategy involves identifying new uses for existing or discontinued drug candidates.
This approach aims to leverage prior research and development investments.

Discussion:

Drug repurposing and the rescue of shelved compounds face significant hurdles.
Key challenges include the diminishing patent exclusivity period for older drugs.
Financial risks associated with late-stage development can deter investment.

Key Insights:

Rescuing shelved compounds requires careful evaluation of their potential beyond original indications.
Approved drugs can be candidates for repurposing, but patent cliffs present a major obstacle.
The economic viability of drug repurposing is a critical consideration for pharmaceutical firms.

Outlook:

Future strategies may involve innovative intellectual property management to extend market exclusivity.
Collaborations between industry and academia could mitigate development risks.
Advancements in predictive modeling and AI may accelerate the identification of viable repurposing candidates.